Genetic or pharmacological inhibition of SREBP1 resulted in cell growth arrest and decreased cell proliferation.24 Recent study reported that inhibition of de novo lipid biosynthesis by suppressing the SREBP pathway prevented HCC progression.37 Our present data also confirmed that decreased TIP30 could promote HCC cell growth via SREBP1-related lipid metabolism in vitro and in vivo, which was also responsible for elevated FASN and SCD expression induced by TIP30 deficiency. The gene discussed is HTATIP2; the disease is hepatocellular carcinoma.